164 related articles for article (PubMed ID: 24222139)
21. Stage IA vs. IB endometrial stromal sarcoma: does the new staging system predict survival?
Garg G; Shah JP; Toy EP; Bryant CS; Kumar S; Morris RT
Gynecol Oncol; 2010 Jul; 118(1):8-13. PubMed ID: 20447684
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis.
Rossi PJ; Jani AB; Horowitz IR; Johnstone PA
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):134-8. PubMed ID: 17855014
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant radiotherapy in incompletely staged IC and II endometrioid uterine cancer.
Parthasarathy A; Kapp DS; Cheung MK; Shin JY; Osann K; Chan JK
Obstet Gynecol; 2007 Dec; 110(6):1237-43. PubMed ID: 18055715
[TBL] [Abstract][Full Text] [Related]
24. [Multivariate analysis of prognostic factors in endometrial carcinoma].
Li B; Wu LY; Li SM; Zhang WH; Zhang R; Ma SK
Ai Zheng; 2004 Sep; 23(9):1085-8. PubMed ID: 15363208
[TBL] [Abstract][Full Text] [Related]
25. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina.
Kosary CL
Semin Surg Oncol; 1994; 10(1):31-46. PubMed ID: 8115784
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: a multi-institutional analysis of 608 women.
Macdonald OK; Sause WT; Lee RJ; Lee CM; Dodson MK; Zempolich K; Gaffney DK
Gynecol Oncol; 2006 Nov; 103(2):661-6. PubMed ID: 16797682
[TBL] [Abstract][Full Text] [Related]
27. Survival of women with surgical stage II endometrial cancer.
Eltabbakh GH; Moore AD
Gynecol Oncol; 1999 Jul; 74(1):80-5. PubMed ID: 10385555
[TBL] [Abstract][Full Text] [Related]
28. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant radiation therapy in stage III node-positive uterine cancer.
Schmid S; Hsu IC; Hu JM; Sherman AE; Osann K; Kapp DS; Chan JK
Gynecol Oncol; 2009 Nov; 115(2):239-43. PubMed ID: 19679341
[TBL] [Abstract][Full Text] [Related]
30. [Combined treatment and prognostic factors for stage III and IV endometrial carcinoma].
Ren YL; Wang HY; Shi DR; Yang WT; Sun Z; Chen Y
Zhonghua Fu Chan Ke Za Zhi; 2008 Jul; 43(7):523-7. PubMed ID: 19080517
[TBL] [Abstract][Full Text] [Related]
31. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
32. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma.
Lee CM; Szabo A; Shrieve DC; Macdonald OK; Gaffney DK
JAMA; 2006 Jan; 295(4):389-97. PubMed ID: 16434629
[TBL] [Abstract][Full Text] [Related]
33. The impact of lymphadenectomy on survival endpoints in women with early stage uterine endometrioid carcinoma: A matched analysis.
Ghanem AI; Khan NT; Mahan M; Ibrahim A; Buekers T; Elshaikh MA
Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():225-230. PubMed ID: 28068595
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer.
Chan JK; Kapp DS; Cheung MK; Shin JY; Stieglitz D; Husain A; Teng NN; Berek JS; Osann K; Guo H
Am J Obstet Gynecol; 2008 Feb; 198(2):216.e1-5. PubMed ID: 18226629
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors for uterine cancer in reproductive-aged women.
Lee NK; Cheung MK; Shin JY; Husain A; Teng NN; Berek JS; Kapp DS; Osann K; Chan JK
Obstet Gynecol; 2007 Mar; 109(3):655-62. PubMed ID: 17329517
[TBL] [Abstract][Full Text] [Related]
36. The impact of race on survival in uterine serous carcinoma: a hospital-based study.
Al-Wahab Z; Ali-Fehmi R; Cote ML; Elshaikh MA; Ibrahim DR; Semaan A; Schultz D; Morris RT; Munkarah AR
Gynecol Oncol; 2011 Jun; 121(3):577-80. PubMed ID: 21377196
[TBL] [Abstract][Full Text] [Related]
37. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
Lutman CV; Havrilesky LJ; Cragun JM; Secord AA; Calingaert B; Berchuck A; Clarke-Pearson DL; Soper JT
Gynecol Oncol; 2006 Jul; 102(1):92-7. PubMed ID: 16406063
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients.
Chan JK; Cheung MK; Huh WK; Osann K; Husain A; Teng NN; Kapp DS
Cancer; 2006 Oct; 107(8):1823-30. PubMed ID: 16977653
[TBL] [Abstract][Full Text] [Related]
39. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy.
Nelson G; Randall M; Sutton G; Moore D; Hurteau J; Look K
Gynecol Oncol; 1999 Nov; 75(2):211-4. PubMed ID: 10525373
[TBL] [Abstract][Full Text] [Related]
40. Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis.
Rauh-Hain JA; Davis M; Clemmer J; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
Gynecol Oncol; 2013 Nov; 131(2):404-9. PubMed ID: 24004647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
